Argenx SE · EURONEXT:ARGX
Argenx — FY2021 Earnings Presentation
17 slides from Argenx's earnings presentation, Mar 3, 2022
Slide 1: Together We Discover
Together We Discover Reaching Patients Through Immunology Innovation Full Year and Fourth Quarter 2021 Financial Results March 3, 2022 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: VYVGART indication in generalized myasthenia gravis
VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive Please see Important Safety Information and the full Prescribing Information for VYVGART at https://vyvgart.com 3
Slide 4: Challenging the gMG Treatment Paradigm
Challenging the gMG Treatment Paradigm ADAPT-NXT Significant Response Rates Demonstrated Safety IV and SC Formulations Individualized Dosing (MG-ADL and QMG scales)
Slide 5: ADAPT-SC Bridging Study to Support Registration
ADAPT-SC Bridging Study to Support Registration Linear correlation between IgG reduction and clinical benefit in gMG Consistent PD effect from efgartigimod whether in healthy volunteers or gMG patients Phase 1 healthy volunteer data showed 1000 mg SC efgartigimod has similar PD effect as 10mg/kg IV
Slide 6: Immune Thrombocytopenia ADVANCE Trials: Two Run in Parallel
Immune Thrombocytopenia ADVANCE Trials: Two Run in Parallel Phase 3, multicenter, randomized, double-blind, placebo-controlled trial N=156 24 weeks 10mg/kg IV efgartigimod Primary Fixed weekly Weekly or q2w dosing adjusted Fixed weekly objective dosing according to platelet count or q2w dosing Durab
Slide 7: Executing on VYVGART Launch Priorities
Executing on VYVGART Launch Priorities Meeting our stakeholders where they are Empower Patients Best-in-Class Rapid HCP Enable to Demand Better Patient Adoption of Appropriate Support VYVGART Access 7
Slide 8: Activating the Patient
Activating the Patient Disease Awareness Accounted for 25% of website visits and 50% of phone call inquiries 8
Slide 9: My VYVGART Path Access Support and Education
My VYVGART Path is Available to Provide Access Support and Education Educate on VYVGART Treatment 90% Financial Personalized Resources of patients have come Assistance and through My VYVGART Support Available Information Path Navigate Insurance Process 9
Slide 10: Increasing Physician Awareness
Increasing Physician Awareness 7.7K* Treat 97% Awareness Neurologists of gMG patients Multi-channel Interest approach to build Engaging with Neurologists experience curve to drive HCPs from 60% Prescribers from Top 1,000 Neurologist Targets HCPs Evaluation awareness to adopting use of VYVGART where
Slide 11: Key Pillars of VYVGART Value-Based Agreement
Key Pillars of VYVGART Value-Based Agreement Affordability Predictability Simplicity The value-based agreement helps provide cost predictability to participating plans aligning interests between patients, physicians and payers VYVGART-specific policies published in plans covering ~25% of covered liv
Slide 12: Global gMG Launch Underway
Global gMG Launch Underway VYVGART Approved December 17, 2021 United States Japan China (Zai Lab) Middle East (GenPharm) Approved Anticipated filing January 20, 2022 in mid-2022 Europe Israel (Medison) Canada Anticipated decision Anticipated filing Global in 2H 2022 in 2Q 2022 12
Slide 13: Full Year 2021 Financial Results
Full Year 2021 Financial Results Year Ended December 31, (in thousands of $ except for shares and EPS) 2021 2020 Variance Revenue $ 497,277 $ 41,243 $ 456,034 Other operating income 42,141 23,668 18,473 Total operating income 539,418 64,911 474,507 Research and development expenses (580,520) (370,88
Slide 14: Global Multifranchise Autoimmune Portfolio
Sjogren’s Congenital MG Global Multifranchise ALS SMA Autoimmune Portfolio MuSK MG Long COVID-19 POTS Efgartigimod MMN Kidney DGF INDICATIONS BP MOLECULES Skin LN ARGX-117 ROW IIM China THERAPEUTIC Israel FRANCHISES Heme MN Europe CIDP Canada PV Neuro ARGX-119 GLOBAL ITP Japan MARKETS gMG US gMG: ge
Slide 15: Pipeline Growth Driven By Immunology Innovation Program
Pipeline Growth Driven By Immunology Innovation Program CLINICAL DEVELOPMENT LEADING ANTIBODY ENGINEERING TRANSLATIONAL BIOLOGY LABS Internal Value Creation Strategy External Value Creation Strategy Staten AgoMAb FIRST IN CLASS | UNIQUE DESIGN | MULTIPLE INDICATIONS ARGX-118 Dualyx (ARGX-116) (ARGX-
Slide 16: argenx: Engineer potentially life-changing immunology therapies
One Team argenx Like the Argonauts, we’re on a bold mission: One Plan Engineer potentially Determined to Achieve the life-changing immunology Unthinkable therapies for patients. 16
Slide 17: Together We Discover
Together We Discover Reaching Patients Through Immunology Innovation 17